Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative IL13-PE38QQR Infusion in Recurrent Malignant Glioma
NCT00041587Phase 2Completed
- Sponsor
- Insys Therapeutics
- Start
- Jul 2002
- Primary completion
- Jun 2006
- Modality
- Immunotoxins, Fc-Fusion Proteins
- Countries
- 3
01
Overview
A Phase 2 trial of cintredekin besudotox in malignant glioma, sponsored by Insys Therapeutics. Started Jul 2002; status: completed.
02
Drugs
cintredekin besudotox
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00041587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041587.